The U.S. Food and Drug Administration has approved Arcutis Biotherapeutics' Zoryve (roflumilast) topical foam 0.3% for the ...

The approval was supported by data from 2 randomized, double-blind, vehicle-controlled trials that included 736 patients aged 12 years and older with mild to severe plaque psoriasis of the scalp and ...

Psoriasis affects your body’s immune system, causing it to produce too many skin cells. Those extra cells build up and create a flaky rash that may appear red, purple, ashen gray, or brown ...

Plaque psoriasis-often mistaken for dry skin or eczema-isn't always easy to manage and usually causes discomfort. Recently, the actress and TV personality opened up to First For Women about her ...

Researchers have found that central body fat, especially around the abdomen, is more strongly linked to psoriasis risk than ...

The trial investigators wanted to see if the drug was an effective psoriasis treatment because of its immune-dampening and itch-reducing effects. A total of 432 patients (56.3% women) aged 12 and ...

Women with psoriasis show shorter drug survival for biologics, including IL-17/23 inhibitors, due to lower satisfaction and more frequent adverse events. The study used the Dutch BioCAPTURE ...

An analysis of a large general practice database showed that patients with severe plaque psoriasis for 3-6 years had a 50% higher relative risk of premature mortality. On average, men and women ...

ICONIC-LEAD is the first ever Phase 3 registrational study in moderate-to-severe plaque psoriasis to assess safety and efficacy of a systemic therapy in adolescents and adults simultaneously 84% ...

Nearly half of patients with moderate-to-severe plaque psoriasis (PsO) treated with investigational icotrokinra achieved completely clear skin (IGA 0) at Week 24 in Phase 3 ICONIC-LEAD Topline ...

Johnson & Johnson (J&J) and Protagonist Therapeutics have announced new data from a late-stage programme of their investigational targeted oral peptide in plaque psoriasis. Results from the phase 3 ...